

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE QUARTER AND 9 MONTHS ENDED 30 SEPTEMBER 2014**

RM'000	3 months ended		9 months ended	
	30.09.14 (Unaudited)	30.09.13 (Unaudited)	30.09.14 (Unaudited)	30.09.13 (Unaudited)
Revenue	497	1,029	1,532	7,101
Other income	(19)	2,571	-	2,701
Operating expenses	(1,907)	(3,157)	(7,764)	(10,984)
Finance costs	-	36	-	1,641
Operating (loss)/profit before tax	<u>(1,429)</u>	<u>479</u>	<u>(6,232)</u>	<u>459</u>
Taxation	-	-	-	1
Net (loss)/profit after tax	<u>(1,429)</u>	<u>479</u>	<u>(6,232)</u>	<u>460</u>
Total comprehensive (expense)/income for the period	<u>(1,429)</u>	<u>479</u>	<u>(6,232)</u>	<u>460</u>
(Loss)/profit attributable to:				
Owners of the Company	(1,371)	542	(6,046)	621
Non-controlling interest	(58)	(63)	(186)	(161)
	<u>(1,429)</u>	<u>479</u>	<u>(6,232)</u>	<u>460</u>
Total comprehensive (expense)/income attributable to:				
Owners of the Company	(1,371)	542	(6,046)	621
Non-controlling interest	(58)	(63)	(186)	(161)
	<u>(1,429)</u>	<u>479</u>	<u>(6,232)</u>	<u>460</u>
(Loss)/earning per share attributable to Owners of the Company (sen):-				
Basic	(0.29)	0.27	(1.38)	0.31
Fully diluted*	<u>(0.29)</u>	<u>0.27</u>	<u>(1.38)</u>	<u>0.31</u>

\* The diluted (loss)/earning per share of the Group is equivalent to the basic (loss)/earning per share as the diluted (loss)/earning per share has anti-dilutive effect.

*The above condensed consolidated statements of profit or loss and other comprehensive income should be read in conjunction with the audited financial statements for the financial period ended 31 December 2013 and the accompanying explanatory notes attached to these interim financial statements.*

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT 30 SEPTEMBER 2014**

<b>RM'000</b>	<b>As at 30.09.14 (Unaudited)</b>	<b>As at 31.12.13 (Audited)</b>
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	39,199	43,101
Deferred tax asset	-	128
	<u>39,199</u>	<u>43,229</u>
<b>Current assets</b>		
Inventories	998	1,151
Trade receivables	2,027	2,272
Other receivables, deposits and prepayments	1,284	393
Tax recoverable	55	55
Fixed deposits with licensed bank	354	345
Cash on hand and at banks	629	2,277
Asset classified as held for sale	1,491	-
	<u>6,838</u>	<u>6,493</u>
<b>TOTAL ASSETS</b>	<u>46,037</u>	<u>49,722</u>
<b>EQUITY AND LIABILITIES</b>		
Share capital	96,432	71,072
ICPS	-	19,613
Accumulated losses	(56,942)	(50,896)
Other reserves	2,741	4,946
Equity attributable to Owners of the Company	<u>42,231</u>	<u>44,735</u>
Non-controlling interest	(502)	(316)
<b>TOTAL EQUITY</b>	<u>41,729</u>	<u>44,419</u>
<b>Non-current liabilities</b>		
ICPS	-	515
	<u>-</u>	<u>515</u>
<b>Current liabilities</b>		
Trade payables	724	904
Other payables and accruals	3,584	3,884
	<u>4,308</u>	<u>4,788</u>
<b>TOTAL LIABILITIES</b>	<u>4,308</u>	<u>5,303</u>
<b>TOTAL EQUITY AND LIABILITIES</b>	<u>46,037</u>	<u>49,722</u>
Net assets per share attributable to owners of the Company (RM)	<u>0.0876</u>	<u>0.1259</u>

*The above condensed consolidated statements of financial position should be read in conjunction with the audited financial statements for the financial period ended 31 December 2013 and the accompanying explanatory notes attached to these interim financial statements.*

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY FOR THE 9 MONTHS ENDED 30 SEPTEMBER 2014**

	<----- Attributable to Owners of the Company ----->					Total	Non- controlling Interest	Total Equity			
	Share Capital	Distributable	<----- Non-Distributable ----->						RM '000	RM '000	RM '000
		Accumulated losses	Share Premium	ICPS	Warrants Reserve						
	RM '000	RM '000	RM '000	RM '000	RM '000	RM '000	RM '000	RM '000			
Balance as of 1 Jan 2014	71,072	(50,896)	2,853	19,613	2,093	44,735	(316)	44,419			
Conversion of ICPS	20,000	-	-	(19,613)	-	387	-	387			
Issuance of shares	5,360	-	-	-	-	5,360	-	5,360			
Shares issuance expenses	-	-	(2,205)	-	-	(2,205)	-	(2,205)			
Total comprehensive expense for the period	-	(6,046)	-	-	-	(6,046)	(186)	(6,232)			
Balance as of 30 September 2014	96,432	(56,942)	648	-	2,093	42,231	(502)	41,729			
<hr/>											
Balance as of 1 Jan 2013	40,000	(32,779)	2,853	-	-	10,074	-	10,074			
Total comprehensive income/(expense) for the period	-	621	-	-	-	621	(161)	460			
Balance as of 30 September 2013	40,000	(32,158)	2,853	-	-	10,695	(161)	10,534			

*The above condensed consolidated statements of changes in equity should be read in conjunction with the audited financial statements for the financial period ended 31 December 2013 and the accompanying explanatory notes attached to these interim financial statements.*

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE 9 MONTHS ENDED 30 SEPTEMBER 2014**

RM'000	9 months ended	
	30.09.14 (Unaudited)	30.09.13 (Unaudited)
<b>CASH FLOWS USED IN OPERATING ACTIVITIES</b>		
Loss before taxation	(6,232)	459
Adjustments for:		
Depreciation of property, plant and equipment	2,527	2,240
Interest waived	-	(1,641)
Unrealised loss on foreign currency exchange	54	(82)
Bad debts recovered	-	(69)
Gain on disposal of property, plant and equipment	-	(20)
Waiver of debts	-	(2,537)
Incorporation fees	-	4
Interest income	(11)	(8)
<b>Operating loss before working capital changes</b>	<b>(3,662)</b>	<b>(1,654)</b>
Decrease in inventories	153	820
(Increase)/decrease in receivables	(646)	996
Decrease in payables	(480)	(1,625)
Cash absorbed by from operations	(4,635)	(1,463)
Interest received	2	8
Interest waived	-	1,641
Incorporation fees paid	-	(4)
Income tax refunded	-	1
<b>Net cash (used in)/from operating activities</b>	<b>(4,633)</b>	<b>183</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchase of property, plant and equipment	(122)	(248)
Proceeds from disposal of property, plant and equipment	6	20
<b>Net cash used in investing activities</b>	<b>(116)</b>	<b>(228)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from issuance of ordinary shares	5,360	-
Shares issuance expenses paid	(2,205)	-
Withdrawal of fixed deposit pledged	-	(9)
<b>Net cash from/(used in) financing activities</b>	<b>3,155</b>	<b>(9)</b>
<b>NET DECREASE IN CASH AND CASH EQUIVALENTS</b>	<b>(1,594)</b>	<b>(54)</b>
EFFECT OF EXCHANGE RATE CHANGES	(54)	82
<b>CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b>	<b>2,277</b>	<b>180</b>
<b>CASH AND CASH EQUIVALENTS AT END OF PERIOD</b>	<b>629</b>	<b>208</b>
<b>CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD COMPRISE:</b>		
Cash and bank balances	629	208
Fixed deposit with licensed banks	354	343
	983	551
Less : Fixed deposit pledged to licensed banks	(354)	(343)
	629	208

*The above condensed consolidated statements of cash flows should be read in conjunction with the audited financial statements for the financial period ended 31 December 2013 and the accompanying explanatory notes attached to these interim financial statements.*

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**NOTES TO THE QUARTERLY REPORT ON CONSOLIDATED RESULT FOR THE PERIOD ENDED 30 SEPTEMBER 2014.**

**A1. BASIS OF PREPARATION**

This condensed consolidated interim financial statements (Condensed Report), other than for financial instruments, have been prepared under the historical cost convention. Certain financial instruments have been carried at fair value in accordance to Malaysian Financial Reporting Standard (MFRS) 139 Financial Instruments: Recognition and Measurement.

This condensed consolidated interim financial statements (Condensed Report) have been prepared in accordance with MFRS 134: Interim Financial Reporting and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

This Condensed Report should be read in conjunction with the audited financial statements for the financial period ended 31 December 2013. The explanatory notes attached to the Condensed Report provide an explanation of events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial period ended 31 December 2013.

**A2. SIGNIFICANT ACCOUNTING POLICIES**

The accounting policies adopted in the preparation of the Condensed Report are consistent with those followed in the preparation of the Group's audited financial statements for the financial period ended 31 December 2013, except for the adoption of Amendments to Standards and Issue Committee (IC) interpretations effective as of 1 January 2014.

Adoption of Amendments to Standards and IC Interpretations

The Group has adopted the following Amendments to Standards and IC Interpretations, with a date of initial application of 1 January 2014.

Amendments to MFRS 10	Consolidated Financial Statements - Investment Entities
Amendments to MFRS 12	Disclosure of Interests in Other Entities - Investment Entities
Amendments to MFRS 127	Separate Financial Statements - Investment Entities
Amendments to MFRS 132	Financial Instruments: Presentation - Offsetting Financial Assets and Financial Liabilities
Amendments to MFRS 136	Impairment of Assets - Recoverable Amount Disclosures for Non-Financial Assets
Amendments to MFRS 139	Novation of Derivatives and Continuation of Hedge Accounting
IC Interpretation 21	Levies

The adoption of the above pronouncements did not have any impact on the financial statements of the Group.

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**A2. SIGNIFICANT ACCOUNTING POLICIES (CONT'D)**

Standards issued but not yet effective

At the date of authorisation of the Condensed Report, the following Standards were issued but not yet effective and have not been adopted by the Group:

**Effective date to be announced by MASB**

MFRS 9	Financial Instruments (IFRS 9 issued by International Accounting Standards Board (IASB) in November 2009)
MFRS 9	Financial Instruments (IFRS 9 issued by IASB in October 2010)
MFRS 9	Financial Instruments: Mandatory Effective Date of MFRS 9 and Transition Disclosures (Amendments to MFRS 9 and MFRS 7)
MFRS 9	Financial Instruments (Hedge Accounting and amendments to MFRS 9, MFRS 7 and MFRS 139)

**Effective for financial periods beginning on or after 1 July 2014**

Amendments to MFRS 119	Defined Benefit Plans: Employee Contributions
Annual Improvements to MFRSs 2010 - 2012 Cycle	
Annual Improvements to MFRSs 2011 - 2013 Cycle	

**Effective for financial periods beginning on or after 1 January 2016**

Amendments to MFRS 10	Consolidated Financial Statements: Sale or Contribution of Assets between an Investor and its Associate or Joint Venture
Amendments to MFRS 11	Joint Arrangements: Accounting for Acquisitions of Interest in Joint Operations
Amendments to MFRS 116	Property, plant and equipment: Clarification of Acceptable Methods of Depreciation and Amortisation
Amendments to MFRS 116	Property, plant and equipment - Agriculture: Bearer Plants
Amendments to MFRS 127	Consolidated and Separate Financial Statements: Equity Method in Separate Financial Statements
Amendments to MFRS 128	Investment in Associates: Sale or Contribution of Assets between an Investor and its Associate or Joint Venture
Amendments to MFRS 138	Intangible Assets: Clarification of Acceptable Methods of Depreciation and Amortisation
MFRS 14	Regulatory Deferral Accounts
MFRS 141	Agriculture: Bearer Plants
Annual Improvements to MFRSs 2012 - 2014 Cycle	

**Effective for financial periods beginning on or after 1 January 2017**

MFRS 15	Revenue from Contracts with Customers
---------	---------------------------------------

**Effective for financial periods beginning on or after 1 January 2018**

MFRS 9	Financial Instruments (IFRS 9 issued by International Accounting Standards Board (IASB) in July 2014)
--------	---

The Group will adopt the above pronouncements when they become effective in the respective financial periods. These pronouncements are not expected to have any effect to the financial statements of the Group upon their initial application, other than for MFRS 9 Financial Instruments. The Group will assess the financial implications of MFRS 9 Financial Instruments when the full standard is issued.

**A3. AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS**

The preceding financial period's audited financial statements of the Group were not subject to any qualification.

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**A4. SEASONAL AND CYCLICAL FACTORS**

The business operations of the Group are subject to the forces of supply and demand, and thus could display cyclical trends.

**A5. UNUSUAL ITEMS AFFECTING ASSETS, LIABILITIES, EQUITY, NET INCOME OR CASH FLOWS**

There were no material items of an unusual nature and amount for the current quarter and 9 months ended 30 September 2014 under review.

**A6. MATERIAL ESTIMATES AND CHANGES IN ESTIMATES**

There were no material changes in the estimates used in the current quarter and 9 months ended 30 September 2014.

**A7. ISSUANCES, CANCELLATIONS, REPURCHASES, RESALE AND REPAYMENTS OF DEBT AND EQUITY SECURITIES**

There were no issuance and repayment of debt and equity securities, share buy-backs, share cancellations and resale of treasury shares for the current quarter and 9 months ended 30 September 2014.

**A8. DIVIDEND PAID**

There were no dividends paid during the current and previous corresponding quarter.

**A9. SEGMENTAL INFORMATION**

Segment information is primarily presented in respect of the Group's business segment which is based on the Group's management and internal reporting structure. Management monitors the operating results of its business segment separately for the purpose of making decision about resource allocation and performance assessment.

(a) Business segment

The principal activities of the Group are those engaged in business of processing, manufacturing and selling drinking water which are substantially within a single business segment. As such, segmental reporting by business segment is deemed not necessary.

(b) Other segment

No other segmental information such as geographical segment, segment assets, segment liabilities and segment results is presented as the Group is principally involved in the manufacturing industry and operates from Malaysia only.

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**A9. SEGMENTAL INFORMATION (CONT'D)**

(c) Major customers

Revenue from major customers with revenue equal or more than 10% of the Group revenue are as follows:

	3 months ended		9 months ended	
	30.09.14	30.09.13	30.09.14	30.09.13
Major customers				
- Customer A	154	-	499	-
- Customer B	-	200	-	1,286
- Customer C	-	-	-	1,057
- Customer D	-	293	-	1,605
- Customer E	52	-	-	1,010

**A10. VALUATION OF PROPERTY, PLANT AND EQUIPMENT**

There was no valuation of property, plant and equipment in the current and previous corresponding quarter.

**A11. EVENTS AFTER THE REPORTING PERIOD**

Material events occurred subsequent to the end of the current quarter are as follows:-

- (a) The Company completed following stages of proposed private placement as mentioned in Note B8 (b):-
- (i) On 2 October 2014, issuance of 5,000,000 new ordinary shares of RM 0.20 each; and
  - (ii) On 14 October 2014, issuance of 11,500,000 new ordinary shares of RM 0.20 each.
- (b) The Company had on 14 October 2014 announced that the Board does not intend to place the remaining Placement Shares as mentioned in Note B8 (b) to potential investors. As a result, the Private Placement is deemed completed as of 14 October 2014.

**A12. RELATED PARTY TRANSACTION**

There were no material related party transaction during the quarter and 9 months ended 30 September 2014.

**A13. CHANGES IN THE COMPOSITION OF THE GROUP**

Other than disclosed below, there were no changes in the composition of the Group during the quarter and 9 months ended 30 September 2014.

The Company had on 19 February 2014 acquired 100% equity interest in Sinaran Strategik Sdn. Bhd. ("Sinaran") (Co. No. 1043077-V) for a total cash consideration of RM 2.00, and hence, Sinaran became a wholly-owned subsidiary company of Bio Osmo Berhad, and subsequently changed its name to Al Maurid Oil & Gas Sdn. Bhd.

**A14. CONTINGENT LIABILITIES AND CONTINGENT ASSETS**

There were no contingent liabilities and assets as at the date of this report.

**A15. CAPITAL COMMITMENT**

There were no capital commitment by the Group during the financial period under review.



**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES**

**B1. REVIEW OF PERFORMANCE**

For the current quarter under review, the Group registered a revenue of RM 0.497 million and loss after tax of RM 1.429 million as compared with a revenue of RM 1.029 million and profit after tax of RM 0.479 million during the corresponding quarter of the previous financial period ended 30 September 2013. The Group's revenue was still low as the Group was still in its recovery stage. The Group continued to face difficulties to retain existing sales in the current moment.

Lower production level during the quarter has also resulted in weak economies of scale, whereas the fixed costs and other overheads remained high. As a result, the Group remained in loss after taxation regime during the current quarter compared to the corresponding quarter.

**B2. MATERIAL CHANGES IN LOSS BEFORE TAXATION AGAINST THE IMMEDIATE PRECEDING QUARTER**

For the current quarter under review, the Group reported a 25.8% increase in revenue to RM 0.497 million, compared to RM 0.395 million recorded during the immediate preceding quarter. The Group reported a loss after taxation of RM 1.429 million against loss after taxation of RM 3.223 million during the immediate preceding quarter. The loss after taxation is significantly lowered compared to the immediate preceding quarter was mainly due to the one-off professional expenses incurred for the acquisition exercise which was incurred in the immediate preceding quarter.

**B3. CURRENT PROSPECTS**

While domestic drinking water market continues to experience stiff competition and margin erosion due to rising operating costs, the Group is turning its focus on the export markets, as well as to widen its product mix to spearhead the sales growth and income stream. Taking advantage of a more solid financial platform, coupled with the efforts to improve its operational efficiencies, the management is upbeat to see an eventual recovery in production levels and financial performances in the future.

The Board realises the difficulties in turning around the existing business operations in the near term. As such, the Board has been actively looking into suitable new businesses through merger and acquisition exercise to complement the existing drinking water business, which can help generate the much needed top and bottom lines for the Group going forward.

**B4. PROFIT FORECAST**

There was no profit forecast for the period under review was required.

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**B5. (LOSS)/PROFIT BEFORE TAXATION**

(Loss)/profit before taxation have been determined after charging/(crediting) amongst other items the following:-

RM '000	3 months ended		9 months ended	
	30.09.14	30.09.13	30.09.14	30.09.13
Depreciation of property, plant and equipment	845	1,434	2,527	2,240
Bad debts recovered	-	-	-	(69)
Incorporation fees	-	4	-	4
Loss/(gain) on foreign currency exchange:				
- unrealised	26	(101)	54	(82)
- realised	2	45	2	68
Gain on disposal of property, plant and equipment	-	(20)	-	(20)
Interest waived	-	-	-	(1,641)
Interest income	(3)	(5)	(11)	(8)
Waiver of debts	-	(2,537)	-	(2,537)

Other than the above, the items listed under Appendix 9B Note 16 of the Listing Requirement of Bursa Malaysia Securities Berhad are not applicable.

**B6. TAXATION**

RM '000	3 months ended		9 months ended	
	30.09.14	30.09.13	30.09.14	30.09.13
Income Tax				
- over provision	-	-	-	(1)
Deferred tax assets	-	-	-	-
	-	-	-	(1)

Domestic income tax is calculated at the Malaysian statutory income tax rate of 25% of the estimated assessable profit for the financial period. In the Budget Speech 2014, the Government announced that the domestic corporate tax rate would be reduced to 24% from the current financial period's rate of 25% with effect from year of assessment of 2016.

**B7. ACCUMULATED LOSSES**

RM '000	As at	As at
	30.09.14	31.12.13
Realised	(69,065)	(62,942)
Unrealised	(54)	43
	(69,119)	(62,899)
Consolidation adjustments	12,177	12,003
<b>Total accumulated losses</b>	<b>(56,942)</b>	<b>(50,896)</b>

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**B8. CORPORATE PROPOSAL**

The corporate proposals occurred during the quarter and 9 months ended 30 September 2014 are as follows:-

- (a) The Company had on 13 January 2014 announced the completion of conversion of 100.0 million Irredeemable Convertible Preference Shares ("ICPS") of RM 0.20 each to 100,000,000 ordinary shares of RM 0.20 each. The new ordinary shares were listed on Bursa Securities on 15 January 2014 and hence, it resulted in an increase of the issued and paid-up capital of the Company from RM 71.072 million or 355,360,000 ordinary shares to RM 91.072 million or 455,360,000 ordinary shares.
- (b) The Company had on 4 March 2014 announced the proposed private placement of up to 48,036,000 new ordinary shares of RM 0.20 each, representing up to 10% of the issued and paid-up share capital of the Company. The stage of completion were as follows:-
  - (i) On 9 June 2014, issuance of 10,000,000 new ordinary shares of RM 0.20 each;
  - (ii) On 23 June 2014, issuance of 11,800,000 new ordinary shares of RM 0.20 each; and
  - (iii) On 18 September 2014, issuance of 5,000,000 new ordinary shares of RM 0.20 each.
- (c) The Company had on 29 May 2014 announced the following corporate proposals which have not been completed as of the date of authorisation of these financial statements:-
  - (i) proposed acquisition of 980,000 ordinary shares of RM 1.00 each in Bayam Enterprise Sdn. Bhd. ("Bayam") for a cash consideration of up to RM 17.15 million ("Proposed Acquisition"); and
  - (ii) proposed diversification of the principal activities of Bio Osmo and its subsidiaries ("Bio Group") to include the provision of catering and hospitality services and other support services to the oil and gas ("O&G") industry pursuant to the proposed acquisition ("Proposed diversification").
- (d) The Company had on 2 September 2014 announced that its wholly-owned subsidiary, Amshore Holdings Sdn. Bhd. ("Amshore") has on the same date entered into a Sale and Purchase Agreement ("the SPA") with BTL Element Sdn. Bhd. ("BTL") for the disposal of two (2) pieces of properties together with all factories and buildings erected thereon for a total sale consideration of RM 3.0 million and on such terms and conditions as stated in the SPA.

**B9. GROUP BORROWINGS**

The Group did not have any borrowings as at the end of the reporting period.

**B10. MATERIAL LITIGATION**

The Group did not have any material litigation as at the end of the reporting period.

**B11. DERIVATIVE FINANCIAL INSTRUMENT**

The Group did not have any derivative financial instrument as at the end of the reporting period.

**B12. OFF BALANCE SHEET FINANCIAL INSTRUMENT**

As at the end of the financial period and up to the date of this announcement, there is no off balance sheet financial instrument which has material impact to the financial statement under review.

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**B13. DIVIDEND PAYABLE**

No interim dividend has been declared for the current financial period to date.

**B14. (LOSS)/EARNING PER SHARE ("LPS)/EPS")**

	<b>3 months ended</b>		<b>9 months ended</b>	
	<b>30.09.14</b>	<b>30.09.13</b>	<b>30.09.14</b>	<b>30.09.13</b>
Net (loss)/earning attributable to Owners of the Company (RM '000)	(1,371)	542	(6,046)	621
Number of ordinary shares in issue ('000)	477,867	200,000	436,741	200,000
Basic (LPS)/EPS (sen)	(0.29)	0.27	(1.38)	0.31
Diluted (LPS)/EPS (sen)	(0.29)	0.27	(1.38)	0.31

**B15. AUTHORISED FOR ISSUE**

The condensed consolidated interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the Directors on 21 November 2014.